Biotechnology

Prelude Therapeutics

Prelude Therapeutics released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 4.58 M (forecast USD 0), actual EPS USD -0.13 (forecast USD -0.2525)

Prelude Therapeutics released FY2025 earnings on March 10 (EST), actual revenue USD 12.14 M (forecast USD 0), actual EPS USD -1.2929 (forecast USD -1.25)

Prelude Therapeutics released FY2025 Q4 earnings on March 10 (EST), actual revenue USD 5.64 M (forecast USD 20.5 M), actual EPS USD -0.2064 (forecast USD -0.03)

Prelude Therapeutics Reports Third Quarter Earnings, Highlights Oncology Pipeline Progress

Prelude Therapeutics released FY2025 Q3 earnings on November 12 During-Market EST, actual revenue USD 6.5 M (forecast USD 0), actual EPS USD -0.259 (forecast USD -0.3666)

Prelude Therapeutics released FY2025 9 Months earnings on November 12 During-Market (EST), actual revenue USD 6.5 M, actual EPS USD -1.0923

Prelude Therapeutics to Release FY2025 Q3 Earnings on November 12 During-Market EST, Forecast EPS USD -0.3666

Prelude Therapeutics to Report Q3 2025 Earnings

Prelude Therapeutics released FY2025 Semi-Annual Earnings on August 14 (EST), with actual revenue of USD 0 and EPS of USD -0.8332

Prelude Therapeutics released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.0099 (forecast USD -0.44)

Prelude Therapeutics Faces Significant Cash Burn Concerns

Prelude Therapeutics released FY2025 Q1 earnings on May 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4222 (forecast USD -0.465)

Prelude Therapeutics Inc expects a loss of 47 cents per share

JPMorgan Reiterates Prelude Therapeutics Outperform Rating

Prelude Therapeutics to Present PRT3789 Preclinical Data at AACR Annual Meeting

Prelude Therapeutics released FY2024 Q4 earnings on March 10 (EST), actual revenue 4 M USD (forecast 0 USD), actual EPS -0.3786 USD (forecast -0.46 USD)

Prelude Therapeutics released FY2024 earnings on March 10 (EST), actual revenue $7M (forecast $1.5M), actual EPS -$1.6776 (forecast -$1.775)

Prelude Therapeutics released FY2024 9 Months Earnings on November 6, 2024 (EST): Actual Revenue USD 3M, Actual EPS USD -1.3039

Prelude Therapeutics released FY2024 Q3 earnings on November 6 (EST), actual revenue $3,000,000 (forecast $0), actual EPS -0.4299 (forecast -0.4733)

QDX collaborates with Prelude Therapeutics

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

GCL Global

Micware

Silexion Therapeutics

MicroAlgo

MetaVia

Vida Global

BiomX

PRLD

SBIO

ARKG

LABU

Prelude Therapeutics has launched a Phase 1 trial for its JAK2V617F inhibitor, PRT12396, after receiving U.S. regulatory clearance. The company reported $84.8 million in cash as of March 31, 2026, and raised $90 million in an offering, extending its cash runway to Q2 2028. Prelude also appointed Charles Morris as chief medical officer and is actively engaging with investors. Analysts rate PRLD stock as a Buy with a $9.00 target, though concerns about financial performance persist. Prelude focuses on developing innovative cancer therapies targeting unmet medical needs.

Tip Ranks

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

Prelude Therapeutics Launches Phase 1 Trial and Extends Runway

Earnings Watch

Prelude Therapeutics | 8-K: FY2026 Q1 Revenue: USD 4.58 M

Prelude Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 4.58 M

INCY

Prelude Therapeutics Inc reported Q1 2026 revenue of $4.58M, a significant increase from $0.0 in Q1 2025, driven by an upfront payment from Incyte. The net loss narrowed to $(10.4) M from $(32.1) M YoY, with diluted EPS improving to $(0.13). The company initiated a Phase 1 trial for PRT12396 and executed a $100M exclusive option agreement with Incyte, with potential milestones of up to $775M. Prelude also raised approximately $90M in equity to support operations for the next year.

TradingView

Incyte

Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary

Prelude Therapeutics pre-market up 8.44%; Lobo Tech pre-market up 86.87%; Local Bounti pre-market up 52.13%; SciSparc pre-market up 50.12%

Price Alert

Pre-market hot trades in US stocks: Prelude Therapeutics pre-market up 8.44%, driven by positive clinical data and dual benefits from new stock issuance boosting stock price surge

Prelude Therapeutics Incorporated (PRLD) has priced its offering of 18.02 million shares at $4.44 each, along with pre-funded warrants for 2.25 million shares at the same price, totaling approximately $90 million. The proceeds will fund research and development, working capital, and capital expenditures. The offering is set to close on April 21, 2026. Prelude's lead candidate, PRT12396, has received IND clearance and is expected to enter Phase 1 trials in 2026. The company has $106 million in cash, providing a runway into Q2 2027. PRLD shares closed at $4.51, up 1.58%.

nasdaq

Goldman Sachs

Evercore

Citizens Financial

Nasdaq

GS Hldg R

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

Prelude Therapeutics Prices Of $90 Mln Offering Of Shares And Pre-Funded Warrants

Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

benzinga_article

Prelude Therapeutics(PRLD.US)